AR072571A1 - Composiciones monovalentes para union a cd28 y procedimientos de uso - Google Patents
Composiciones monovalentes para union a cd28 y procedimientos de usoInfo
- Publication number
- AR072571A1 AR072571A1 ARP090102734A ARP090102734A AR072571A1 AR 072571 A1 AR072571 A1 AR 072571A1 AR P090102734 A ARP090102734 A AR P090102734A AR P090102734 A ARP090102734 A AR P090102734A AR 072571 A1 AR072571 A1 AR 072571A1
- Authority
- AR
- Argentina
- Prior art keywords
- domain
- activity
- domain antibody
- union
- procedures
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
Abstract
Anticuerpos de dominio que se unen de forma monovalente a CD28. Los anticuerpos de dominio que son monovalentes para la union a CD28 pueden inhibir la actividad de CD28. En un aspecto, un anticuerpo de dominio está constituido por o comprende un dominio variable de inmunoglobulina unico que se une específicamente y antagoniza la actividad de CD28 y, en un aspecto, sin agonizar sustancialmente la actividad de CD28. En otro aspecto, el anticuerpo de dominio es un anticuerpo de dominio humano. La descripcion incluye adicionalmente procedimientos para antagonizar las interacciones de CD80 y/o CD86 con CD28 en un individuo y procedimientos para tratar enfermedades o trastornos que implican interacciones de CD80 y/o CD86 con CD28, implicando los procedimientos la administracion de un anticuerpo de dominio al individuo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8207808P | 2008-07-18 | 2008-07-18 | |
US16212109P | 2009-03-20 | 2009-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072571A1 true AR072571A1 (es) | 2010-09-08 |
Family
ID=41226147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102734A AR072571A1 (es) | 2008-07-18 | 2009-07-17 | Composiciones monovalentes para union a cd28 y procedimientos de uso |
Country Status (30)
Country | Link |
---|---|
US (6) | US8168759B2 (es) |
EP (2) | EP2321352B1 (es) |
JP (3) | JP5675608B2 (es) |
KR (2) | KR101660057B1 (es) |
CN (2) | CN105936648B (es) |
AR (1) | AR072571A1 (es) |
AU (1) | AU2009270726B2 (es) |
CA (1) | CA2731220C (es) |
CL (2) | CL2011000117A1 (es) |
CO (1) | CO6341641A2 (es) |
CY (1) | CY1121796T1 (es) |
DK (2) | DK2321352T3 (es) |
EA (1) | EA024585B1 (es) |
ES (2) | ES2562629T3 (es) |
HK (1) | HK1155178A1 (es) |
HR (2) | HRP20160329T1 (es) |
HU (2) | HUE029982T2 (es) |
IL (2) | IL210413A (es) |
LT (1) | LT2700651T (es) |
ME (1) | ME02396B (es) |
MX (1) | MX2011000501A (es) |
NZ (1) | NZ590343A (es) |
PE (2) | PE20110385A1 (es) |
PL (2) | PL2321352T3 (es) |
PT (2) | PT2321352E (es) |
RS (2) | RS54675B1 (es) |
SI (2) | SI2700651T1 (es) |
SM (1) | SMT201600090B (es) |
TW (2) | TWI450725B (es) |
WO (1) | WO2010009391A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2479191A3 (en) | 2005-05-18 | 2013-03-13 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
US20110097339A1 (en) * | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
AU2009270726B2 (en) | 2008-07-18 | 2015-07-09 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
RU2540010C2 (ru) * | 2009-02-25 | 2015-01-27 | Некстера АС | НЕЗАВИСИМЫЙ ОТ СИГНАЛЬНОЙ ПОСЛЕДОВАТЕЛЬНОСТИ ФАГОВЫЙ ДИСПЛЕЙ НА БЕЛКЕ pIX |
FR2951176A1 (fr) * | 2009-10-09 | 2011-04-15 | Tcl Pharma | Ligands monovalents du recepteur cd28 humain |
EP2536764B1 (en) | 2010-02-18 | 2018-07-04 | OSE Immunotherapeutics | Anti-cd28 humanized antibodies |
EP2361935A1 (en) * | 2010-02-18 | 2011-08-31 | TcL Pharma | Anti-CD28 humanized antibodies |
WO2011156328A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JP5768022B2 (ja) * | 2012-03-19 | 2015-08-26 | 株式会社東芝 | メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法 |
WO2014120916A1 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Pegylated domain antibodies monovalent for cd28 binding and methods of use |
EP3088411A4 (en) * | 2013-12-27 | 2018-12-19 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying antibody having low isoelectric point |
KR20160124912A (ko) * | 2014-03-19 | 2016-10-28 | 브리스톨-마이어스 스큅 컴퍼니 | Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법 |
TW201625688A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 經半胱胺酸改造之抗體及接合物 |
WO2016054218A1 (en) | 2014-09-30 | 2016-04-07 | Bristol-Myers Squibb Company | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 |
WO2017160975A1 (en) | 2016-03-16 | 2017-09-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
CN112638375A (zh) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | 通过后细胞信号传导因子的调节来增加免疫活性 |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
WO2020028764A1 (en) | 2018-08-03 | 2020-02-06 | Bristol-Myers Squibb Company | Methods for detecting anti-drug antibodies |
AU2019383976A1 (en) | 2018-11-19 | 2021-06-10 | Biora Therapeutics, Inc. | Methods and devices for treating a disease with biotherapeutics |
CN113710704A (zh) * | 2019-03-14 | 2021-11-26 | 比昂生物制剂公司 | 小脱落阻断剂 |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
KR20220108137A (ko) * | 2019-12-02 | 2022-08-02 | 비온드 바이오로직스 엘티디 | Mmp 억제의 용도 |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
AU2021213177A1 (en) * | 2020-01-29 | 2022-08-18 | Inhibrx Biosciences, Inc. | CD28 single domain antibodies and multivalent and multispecific constructs thereof |
CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
JP2023536630A (ja) * | 2020-08-04 | 2023-08-28 | エグゼリクシス, インコーポレイテッド | Pd-l1結合性作用剤およびその使用 |
EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
AU2022341016A1 (en) * | 2021-09-06 | 2024-04-18 | Biond Biologics Ltd. | Cd28 shedding blocking agents |
TW202400659A (zh) * | 2022-05-04 | 2024-01-01 | 美商詹努克斯治療有限公司 | 經腫瘤活化之靶向cd28及pd-l1之多特異性抗體及其使用方法 |
WO2023215498A2 (en) * | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
WO2024077118A2 (en) | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839295A (en) | 1984-06-08 | 1989-06-13 | Pierce Chemical Company | Measurement of protein using bicinchoninic acid |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
ES2322324T3 (es) | 1992-08-21 | 2009-06-19 | Vrije Universiteit Brussel | Inmumoglobulinas desprovistas de cadenas ligeras. |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
ES2159726T3 (es) | 1995-03-10 | 2001-10-16 | Roche Diagnostics Gmbh | Formas de administracion farmaceuticas que contienen polipeptidos, en forma de microparticulas, y procedimiento para su fabricacion. |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
CA2292415A1 (en) | 1997-06-20 | 1998-12-30 | Innogenetics N.V. | B7-binding molecules for treating immune diseases |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
DE69921636T2 (de) | 1998-04-20 | 2005-11-03 | Genzyme Corp., Cambridge | Medikamentöse verabreichung von proteinen aus polymergemischen |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
AU4770300A (en) | 1999-05-14 | 2000-12-05 | Medical Research Council | Protein scaffold and its use to multimerise monomeric polypeptides |
US20020006403A1 (en) * | 1999-12-14 | 2002-01-17 | Xue-Zhong Yu | CD28-specific antibody compositions for use in methods of immunosuppression |
DE60142794D1 (de) * | 2000-12-26 | 2010-09-23 | Inst Nat Sante Rech Med | Antikörper gegen cd28 |
US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
WO2002066059A2 (en) | 2001-02-16 | 2002-08-29 | Genetics Institute, Llc | Agents that specifically block cd28-mediated signaling and uses therefor |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
WO2004058821A2 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
DK1419179T3 (da) | 2001-08-10 | 2010-06-21 | Univ Aberdeen | Antigenbindingsdomæner fra fisk |
WO2003031611A2 (en) | 2001-10-05 | 2003-04-17 | Cangene Corporation | Phagemid display system |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
DE10156482A1 (de) * | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
US7635472B2 (en) | 2003-05-31 | 2009-12-22 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
CN101061140B (zh) * | 2004-09-17 | 2015-07-01 | 多曼蒂斯有限公司 | 单价结合cd40l的组合物和应用方法 |
GB0614093D0 (en) | 2006-07-14 | 2006-08-23 | Bae Systems Plc | Deployable antenna system |
CA2672595A1 (en) * | 2006-12-15 | 2008-06-19 | Guy Hermans | Amino acid sequences that modulate the interaction between cells of the immune system |
AU2009270726B2 (en) | 2008-07-18 | 2015-07-09 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
AU2009284113B2 (en) | 2008-08-21 | 2015-05-14 | Octapharma Ag | Recombinantly produced human factor VIII and IX |
KR20160124912A (ko) * | 2014-03-19 | 2016-10-28 | 브리스톨-마이어스 스큅 컴퍼니 | Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법 |
WO2016054218A1 (en) * | 2014-09-30 | 2016-04-07 | Bristol-Myers Squibb Company | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 |
-
2009
- 2009-07-17 AU AU2009270726A patent/AU2009270726B2/en not_active Ceased
- 2009-07-17 ES ES09790582.2T patent/ES2562629T3/es active Active
- 2009-07-17 TW TW098124305A patent/TWI450725B/zh not_active IP Right Cessation
- 2009-07-17 WO PCT/US2009/050985 patent/WO2010009391A1/en active Application Filing
- 2009-07-17 HU HUE09790582A patent/HUE029982T2/en unknown
- 2009-07-17 EP EP09790582.2A patent/EP2321352B1/en active Active
- 2009-07-17 ES ES13185422T patent/ES2730727T3/es active Active
- 2009-07-17 PT PT97905822T patent/PT2321352E/pt unknown
- 2009-07-17 PE PE2011000053A patent/PE20110385A1/es active IP Right Grant
- 2009-07-17 AR ARP090102734A patent/AR072571A1/es active IP Right Grant
- 2009-07-17 JP JP2011518935A patent/JP5675608B2/ja active Active
- 2009-07-17 LT LTEP13185422.6T patent/LT2700651T/lt unknown
- 2009-07-17 PL PL09790582T patent/PL2321352T3/pl unknown
- 2009-07-17 PL PL13185422T patent/PL2700651T3/pl unknown
- 2009-07-17 SI SI200931964T patent/SI2700651T1/sl unknown
- 2009-07-17 US US12/505,166 patent/US8168759B2/en active Active
- 2009-07-17 PE PE2014000192A patent/PE20140852A1/es not_active Application Discontinuation
- 2009-07-17 SI SI200931383T patent/SI2321352T1/sl unknown
- 2009-07-17 CA CA2731220A patent/CA2731220C/en not_active Expired - Fee Related
- 2009-07-17 CN CN201610344002.1A patent/CN105936648B/zh active Active
- 2009-07-17 EA EA201100239A patent/EA024585B1/ru not_active IP Right Cessation
- 2009-07-17 ME MEP-2016-76A patent/ME02396B/me unknown
- 2009-07-17 RS RS20160200A patent/RS54675B1/en unknown
- 2009-07-17 CN CN2009801358711A patent/CN102159590A/zh active Pending
- 2009-07-17 EP EP13185422.6A patent/EP2700651B1/en active Active
- 2009-07-17 NZ NZ590343A patent/NZ590343A/xx unknown
- 2009-07-17 HU HUE13185422A patent/HUE045249T2/hu unknown
- 2009-07-17 PT PT13185422T patent/PT2700651T/pt unknown
- 2009-07-17 KR KR1020117003660A patent/KR101660057B1/ko active IP Right Grant
- 2009-07-17 RS RS20190631A patent/RS58904B1/sr unknown
- 2009-07-17 DK DK09790582.2T patent/DK2321352T3/en active
- 2009-07-17 MX MX2011000501A patent/MX2011000501A/es active IP Right Grant
- 2009-07-17 KR KR1020167025702A patent/KR101791372B1/ko active IP Right Grant
- 2009-07-17 TW TW101147598A patent/TW201336510A/zh unknown
- 2009-07-17 DK DK13185422.6T patent/DK2700651T3/da active
-
2010
- 2010-12-30 IL IL210413A patent/IL210413A/en active IP Right Grant
-
2011
- 2011-01-18 CL CL2011000117A patent/CL2011000117A1/es unknown
- 2011-02-15 CO CO11017973A patent/CO6341641A2/es active IP Right Grant
- 2011-09-02 HK HK11109298.7A patent/HK1155178A1/zh not_active IP Right Cessation
-
2012
- 2012-03-09 US US13/415,914 patent/US9085629B2/en active Active
- 2012-03-09 US US13/416,033 patent/US8454959B2/en active Active
- 2012-08-31 CL CL2012002428A patent/CL2012002428A1/es unknown
-
2014
- 2014-12-24 JP JP2014261305A patent/JP5876134B2/ja active Active
-
2015
- 2015-06-16 US US14/740,709 patent/US9908937B2/en active Active
-
2016
- 2016-01-20 JP JP2016009024A patent/JP6058833B2/ja active Active
- 2016-03-29 SM SM201600090T patent/SMT201600090B/xx unknown
- 2016-04-01 HR HRP20160329TT patent/HRP20160329T1/hr unknown
-
2017
- 2017-03-21 IL IL251320A patent/IL251320B/en active IP Right Grant
-
2018
- 2018-01-12 US US15/870,121 patent/US10919965B2/en active Active
-
2019
- 2019-05-28 HR HRP20190966TT patent/HRP20190966T1/hr unknown
- 2019-07-09 CY CY20191100722T patent/CY1121796T1/el unknown
-
2020
- 2020-11-02 US US17/086,565 patent/US12012452B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072571A1 (es) | Composiciones monovalentes para union a cd28 y procedimientos de uso | |
AR073459A1 (es) | Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso | |
BR112012023010A8 (pt) | Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37 | |
CL2020000452A1 (es) | Anticuerpos de b7-h4 y métodos para usarlos. | |
CL2020001974A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093) | |
PE20181349A1 (es) | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador | |
CO2017011486A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
AR077333A1 (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana | |
AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
AR083044A1 (es) | Anticuerpos anti-cd48 y usos de los mismos | |
BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
MX2014001799A (es) | Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso. | |
CO2018003852A2 (es) | Proteínas de unión a antigeno que activan el receptor de leptina | |
AR084315A1 (es) | Anticuerpos anti-notch1 | |
CY1118551T1 (el) | Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4 | |
AR085600A1 (es) | Agentes de union biespecifica | |
RS54795B1 (sr) | Anti-her3 antitela i njihova korišćenja | |
EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
PE20091520A1 (es) | Anticuerpos bivalentes biespecificos | |
AU2014247175A8 (en) | Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use | |
PE20141158A1 (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapeutico | |
PE20141659A1 (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc | |
PE20081478A1 (es) | Anticuerpos cd44 | |
BR112013031485A8 (pt) | Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais | |
BR112022009723A2 (pt) | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |